Experts are increasingly examining retatrutide, a innovative drug created by Eli Lilly, as a significant advance in body management. Unlike many previous approaches, retatrutide is a double -action compound targeting equally GLP-1 and GIP, hormones that affect hunger and blood glucose balance. Earl